Incyte Corporation (INCY) vs Insmed, Inc. (INSM)
Incyte Corporation and Insmed, Inc. are both Biotechnology companies. Incyte Corporation and Insmed, Inc. are of similar size ($26.8B and $25.5B). Insmed, Inc. has negative trailing earnings, so its P/E is not meaningful; Incyte Corporation trades at 15.2×. Insmed, Inc. grew revenue faster over the last twelve months: 185.8% against 26.9%. Incyte Corporation has the higher net margin (27.7% vs −76.9%) and the higher return on invested capital (60.5% vs −329.2%). Across the 18 metrics below, Incyte Corporation leads on 16 and Insmed, Inc. on 2.
Valuation
Profitability
| Metric | INCY | INSM | Biotechnology median |
|---|---|---|---|
| Gross margin | 92.62% | 83.46% | 65.16% |
| Operating margin | 30.56% | (73.89%) | 0.00% |
| Net margin | 27.71% | (76.94%) | 0.00% |
| Free cash flow margin | 32.48% | (71.00%) | 0.00% |
| Return on equity | 30.67% | (87.22%) | (57.72%) |
| Return on assets | 23.55% | (38.20%) | (49.22%) |
| Return on invested capital | 60.50% | (329.22%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack